title: Transmitter mediation of the anxiolytic action of apelin-13 in male mice.
abstract: The widespread distribution of apelin-13 and apelin receptors in the brain and periphery suggests an important function of this neuropeptide in regulatory processes in the organism. In previous work we found that apelin-13 facilitates the consolidation of passive avoidance learning in rats. In the present work we demonstrate that apelin-13 exerts anxiolytic action in an elevated plus maze in mice. In order to assess the possible involvement of transmitters in this action, the animals were pretreated with the following receptor blockers in doses which themselves did not influence the behavioral paradigm: atropine (a nonselective muscarinic acetylcholine receptor antagonist), haloperidol (a D2, D3, D4 dopamine receptor antagonist), phenoxybenzamine (a nonselective α1-adrenergic receptor antagonist), methysergide (a nonselective 5-HT2 serotonergic receptor antagonist), propranolol (a β-adrenergic receptor antagonist), naloxone (a nonselective opioid receptor antagonist) and bicuculline (a γ-aminobutyric acid subunit A receptor antagonist. Phenoxybenzamine, haloperidol, propranolol and methysergide prevented the action of apelin-13, whereas atropine, naloxone and bicuculline were ineffective. The data suggest that apelin-13 elicits its anxiolytic action via α-adrenergic, dopaminergic, β-adrenergic and 5-HT2 serotonergic mediation.
authors: Department of Pathophysiology, University of Szeged, Szeged, Hungary; Neuroscience Research Group of the Hungarian Academy of Sciences, University of Szeged, Szeged, Hungary. Electronic address: Telegdy.Gyula@med.u-szeged.hu.
authors: Gyula
authors: G
authors: Telegdy
authors: Department of Pathophysiology, University of Szeged, Szeged, Hungary.
authors: Miklós
authors: M
authors: Jászberényi
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001007:Anxiety / Q000188:drug therapy / Q000503:physiopathology*; D001285:Atropine / Q000494:pharmacology; D001640:Bicuculline / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D058787:GABA-A Receptor Antagonists / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D036341:Intercellular Signaling Peptides and Proteins / Q000008:administration & dosage* / Q000378:metabolism*; D008297:Male; D018782:Maze Learning / Q000187:drug effects / Q000502:physiology*; D008784:Methysergide / Q000494:pharmacology; D051379:Mice; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D017981:Receptors, Neurotransmitter / Q000378:metabolism; D012702:Serotonin Antagonists / Q000494:pharmacology
chemical_list: D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D018492:Dopamine Antagonists; D058787:GABA-A Receptor Antagonists; D036341:Intercellular Signaling Peptides and Proteins; D018727:Muscarinic Antagonists; D009292:Narcotic Antagonists; D017981:Receptors, Neurotransmitter; D012702:Serotonin Antagonists; C495199:apelin-13 peptide; D010643:Phenoxybenzamine; D009270:Naloxone; D001285:Atropine; D011433:Propranolol; D006220:Haloperidol; D008784:Methysergide; D001640:Bicuculline
keywords: Anxiolytic action; Apelin-13; Tranmitter mediation